Joshua Jennings
Stock Analyst at TD Cowen
(3.38)
# 926
Out of 4,896 analysts
68
Total ratings
46.03%
Success rate
5.4%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $3.17 | +373.19% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $289.32 | +11.99% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $103.20 | +6.59% | 7 | Dec 12, 2024 | |
| CBLL CeriBell | Maintains: Buy | $31 → $36 | $16.18 | +122.50% | 2 | Dec 9, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $112.46 | +6.70% | 9 | Nov 18, 2024 | |
| HUMA Humacyte | Reiterates: Buy | $10 | $2.31 | +332.90% | 2 | Oct 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $50 | $2.84 | +1,660.56% | 1 | Oct 2, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $75 → $99 | $56.65 | +74.76% | 3 | Sep 16, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Hold | $143 → $119 | $93.79 | +26.88% | 1 | Sep 6, 2024 | |
| VCEL Vericel | Maintains: Buy | $55 → $60 | $39.93 | +50.26% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $81.78 | -2.18% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $19.39 | +132.08% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $78.05 | -10.31% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $156.90 | +17.91% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $28.70 | +39.37% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $389.46 | +2.71% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $44.89 | +33.66% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $15.59 | +118.09% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $5.81 | +209.81% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $83.37 | +49.93% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $20.07 | +24.56% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $132.02 | -1.53% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.25 | +122.22% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $89.92 | +30.12% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $8.09 | +5,462.42% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $10.99 | +9.19% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $175.97 | +56.28% | 1 | Feb 7, 2020 |
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $3.17
Upside: +373.19%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $289.32
Upside: +11.99%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $103.20
Upside: +6.59%
CeriBell
Dec 9, 2024
Maintains: Buy
Price Target: $31 → $36
Current: $16.18
Upside: +122.50%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $112.46
Upside: +6.70%
Humacyte
Oct 18, 2024
Reiterates: Buy
Price Target: $10
Current: $2.31
Upside: +332.90%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $2.84
Upside: +1,660.56%
PROCEPT BioRobotics
Sep 16, 2024
Maintains: Buy
Price Target: $75 → $99
Current: $56.65
Upside: +74.76%
Zimmer Biomet Holdings
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $93.79
Upside: +26.88%
Vericel
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $39.93
Upside: +50.26%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $81.78
Upside: -2.18%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $19.39
Upside: +132.08%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $78.05
Upside: -10.31%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $156.90
Upside: +17.91%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $28.70
Upside: +39.37%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $389.46
Upside: +2.71%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $44.89
Upside: +33.66%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $15.59
Upside: +118.09%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $5.81
Upside: +209.81%
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $83.37
Upside: +49.93%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $20.07
Upside: +24.56%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $132.02
Upside: -1.53%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.25
Upside: +122.22%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $89.92
Upside: +30.12%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $8.09
Upside: +5,462.42%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $10.99
Upside: +9.19%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $175.97
Upside: +56.28%